Business
Isodiol International Inc. Provides Update for Shareholders; Announces Extension of Deadline for Biosynthesis Pharma Group Acquisition
Isodiol International Inc. Provides Update for Shareholders; Announces Extension of Deadline for Biosynthesis Pharma Group Acquisition.
About this update from Isodiol International Inc
[{"type":"text","content":"\n\n VANCOUVER, British Columbia, April 03, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive CBD innovator specializing in the development of pharmaceutical and wellness products, announces that it is has extended the period to complete the acquisition of Biosynthesis Pharma Group (BSPG) to April 30, 2018. \n The Company announced in March that it has successfully performed all of the due diligence set out in the binding agreement to acquire BSPG and is currently in final stages of executing the closing documents. For more information on Isodiol, please visit www.isodiol.com. About Isodiol International Inc. Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products. Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products. Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe. Join Us On Facebook: https://www.facebook.com/isodiol/Twitter: @isodiol  ON BEHALF OF THE BOARDMarcos Agramont, CEO & Director INVESTOR RELATIONS:[email protected] Forward-Looking Information: This news release contains \"forward-looking information\" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depen...